You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Some believe that more could be done to help deliver diagnostics to the European market.
VALUE-Dx involves six IVD companies and is being heralded by participants as an opportunity for competitors to work together to improve test adoption.
Value-Dx is being spearheaded by six in vitro diagnostic firms and 20 non-industry partners and will be funded with with €14 million over four years.
The panel is designed to measure genetic markers in whole-blood samples in order to predict which patients are likely to experience a severe, relapsing form of the disease.